Bionow | News

Charles River Integrates Cell and Gene Therapy Acquisitions to Enhance End-to-En...

Jan 11th 2022

In March 2021, Cobra and Cognate officially joined the Charles River family and in January 2022, launched the rebranding of our businesses into Charles River.

CG01-GMP plasmids released - Ready to start GMP production of CG01

Jun 24th 2021

The plasmids have been released at Cobra and are ready to be used as starting material for the GMP batch that will be used in the first clinical study scheduled to begin in 2022.

Albumedix extends research collaboration with Cobra Biologics

Jun 24th 2021

Process optimization and stability enhancement in scale-up manufacturing of AAV and lentiviral vectors through Albumedix' proprietary recombinant human albumin-based product

Charles River Laboratories Completes the Acquisition of Cognate BioServices

Mar 30th 2021

Cognate BioServices and its subsidiary Cobra Biologics have been acquired by Charles River

Cognate BioServices, and its gene therapy division Cobra Biologics, Announce Maj...

Jan 19th 2021

Cobra is undertaking a multi-phase augmentation of its plasmid DNA services as a continuation of its Advanced Therapy expansion project

Cobra Biologics completes production of Master Cell Banks for CombiGene’s epil...

Aug 18th 2020

Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks

Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID...

Jun 17th 2020

Providing large scale manufacturing capacity for AZD1222

Cobra Biologics is proud to be part of a consortium to rapidly develop a COVID-1...

Mar 31st 2020

ChAdOx1 consortium, led by the Jenner Institute, working to produce adenoviral vaccine with fast-tracked clinical trials to begin in April 2020

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 va...

Mar 31st 2020

OPENCORONA consortium awarded €3million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collabor...

Jun 25th 2019

Developing world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy.

Cobra Biologics expands DNA vaccines, gene and immunotherapy production in Swede...

Apr 11th 2019

ATMP (Advanced therapy medicinal product) specialist Cobra Biologics builds Sweden’s first 500 litre bioreactor investing €20 million at its Matfors facility in Sundsvall.

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1...

Nov 26th 2018

Cobra Biologics, an international contract development and manufacturing organisation with a focus on advanced therapy medicinal products has won a £1.5m shared grant from Innovate UK.

News